August 25, 2020 -- AbbVie and Harvard University announced a $30 million collaborative research alliance to study therapies against emerging viral infections.
The announcement launches an effort at Harvard Medical School to begin studying treatments for newly forming viral infections, specifically those caused by coronaviruses and ones that lead to hemorrhagic fever. The cataclysmic nature of the COVID-19 pandemic reinforced the need for scientists to prepare for the next public health crisis.
AbbVie will provide $30 million over three years, as well as support from its scientists, expertise, and facilities, to advance collaborative research and early-stage development across the following five programs:
- Immunity and immunopathology
- Small molecules
- Host targeting for antiviral therapies
- Antibody therapeutics
- Translational development
Copyright © 2020 scienceboard.net